Multiple Sclerosis: A Complete Guide to Understanding, Treating, and Living With MS

A diagnosis of multiple sclerosis can feel overwhelming. The disease is unpredictable, the symptoms are varied, and the medical terminology alone can be hard to navigate. But here is something important to hold onto: the treatment landscape for MS has changed dramatically over the past two decades. People diagnosed today have access to more than 20 disease-modifying therapies, better diagnostic tools, and a growing body of evidence on lifestyle strategies that can genuinely improve outcomes.

This guide is designed to give you a clear, thorough understanding of MS, whether you have been recently diagnosed, are supporting a loved one, or simply want to learn. We will cover what happens in the body, the different forms the disease can take, how it is diagnosed, the full spectrum of treatments, and the integrative approaches that research supports.

What Is Multiple Sclerosis?

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS), which includes the brain, spinal cord, and optic nerves. In MS, the immune system mistakenly attacks myelin, the fatty protective sheath that insulates nerve fibers and allows electrical signals to travel quickly and efficiently along them.

When myelin is damaged (a process called demyelination), the underlying nerve fibers can also be injured. This disrupts communication between the brain and the rest of the body. The specific symptoms a person experiences depend on which nerves are affected and how severely they are damaged (Thompson et al., 2018).

The areas of damage are called lesions or plaques, and they can appear anywhere in the CNS. Over time, the accumulated damage can lead to axonal degeneration, meaning the nerve fibers themselves are destroyed, not just their protective coating. This axonal loss is thought to be the main driver of permanent disability in MS and is why early, aggressive treatment has become increasingly important (Reich et al., 2018).

Types of Multiple Sclerosis

MS does not follow a single pattern. The disease is categorized into several types based on how it progresses over time.

Clinically Isolated Syndrome (CIS)

CIS refers to a first episode of neurological symptoms caused by inflammation and demyelination in the CNS. It lasts at least 24 hours and may involve optic neuritis (vision problems), transverse myelitis (spinal cord inflammation), or brainstem symptoms. Not everyone with CIS goes on to develop MS, but if MRI shows lesions characteristic of MS, the risk of a second episode is high. Many neurologists now recommend starting DMT at the CIS stage if the risk profile is concerning (Miller et al., 2012).

Relapsing-Remitting MS (RRMS)

This is the most common form, accounting for about 85 percent of initial diagnoses. RRMS is characterized by clearly defined relapses (also called attacks, flares, or exacerbations), during which new symptoms appear or existing ones worsen. Relapses are followed by periods of partial or complete recovery (remission). Between relapses, the disease does not appear to progress. RRMS is the form most responsive to currently available DMTs.

Secondary Progressive MS (SPMS)

Many people with RRMS eventually transition to SPMS, in which disability gradually worsens over time with or without relapses. The transition typically happens 10 to 20 years after initial diagnosis, though early treatment with DMTs may delay or prevent this transition. SPMS can be further classified as “active” (with relapses or new MRI activity) or “not active.”

Primary Progressive MS (PPMS)

Affecting about 10 to 15 percent of people with MS, PPMS is characterized by a steady worsening of neurological function from the onset, without distinct relapses or remissions. PPMS tends to be diagnosed later in life (often in the 40s or 50s) and affects men and women roughly equally, unlike RRMS, which is two to three times more common in women. Treatment options for PPMS have historically been limited, but ocrelizumab became the first DMT approved specifically for this form (Montalban et al., 2017).

Symptoms of Multiple Sclerosis

MS symptoms are extraordinarily varied because lesions can occur anywhere in the central nervous system. Two people with MS may have completely different symptom profiles. Here are the most common ones.

Fatigue

This is the single most commonly reported symptom, affecting up to 80 percent of people with MS. MS-related fatigue is different from ordinary tiredness. It can come on suddenly, is often disproportionate to activity level, and may significantly interfere with daily functioning. It is one of the leading causes of work disability in MS (Penner & Paul, 2017).

Vision Problems

Optic neuritis, inflammation of the optic nerve, is often an early symptom. It typically causes pain with eye movement, blurred or dimmed vision in one eye, and sometimes temporary color vision loss. Other visual symptoms include double vision (diplopia) and involuntary eye movements (nystagmus).

Numbness and Tingling

Sensory symptoms are very common and may be the first sign of MS. People describe numbness, tingling, “pins and needles,” burning sensations, or a tight banding feeling around the torso or limbs. Lhermitte’s sign, an electric shock-like sensation running down the spine when bending the neck, is particularly characteristic of MS.

Muscle Weakness

Weakness can affect any part of the body but most commonly involves the legs. It may cause foot drop, difficulty climbing stairs, or problems with grip strength. Weakness results from damaged nerve pathways that can no longer efficiently transmit signals from the brain to the muscles.

Balance and Coordination Problems

Damage to the cerebellum or its connections causes ataxia, which leads to unsteady gait, poor coordination, and tremor. Balance issues are a major contributor to falls, which are a significant concern for people with MS.

Cognitive Changes

About 50 percent of people with MS experience some degree of cognitive change, most commonly affecting processing speed, memory, and attention. Executive function and verbal fluency can also be impaired. Cognitive symptoms can occur at any stage of the disease and may be present even when physical disability is minimal (Chiaravalloti & DeLuca, 2008).

Bladder and Bowel Dysfunction

Bladder problems affect up to 80 percent of people with MS and include urgency, frequency, incontinence, and difficulty emptying the bladder completely. Constipation is the most common bowel complaint. These symptoms are often underreported because of embarrassment, but effective treatments exist.

Spasticity

Spasticity refers to muscle stiffness, involuntary spasms, and increased muscle tone. It most often affects the legs and can range from mild tightness to severe, painful spasms that interfere with mobility and sleep.

Pain

Contrary to early beliefs that MS was painless, research shows that up to 75 percent of people with MS experience pain at some point. Types include neuropathic pain (burning, stabbing, or shooting), trigeminal neuralgia, musculoskeletal pain related to immobility or gait changes, and painful tonic spasms.

Uhthoff’s Phenomenon

This is a temporary worsening of symptoms triggered by increased body temperature, whether from exercise, hot baths, fever, or hot weather. It occurs because heat slows nerve conduction in demyelinated fibers. The symptoms are not a sign of a relapse and resolve when body temperature returns to normal.

How MS Is Diagnosed

There is no single test for MS. Diagnosis is based on the McDonald criteria, which require evidence of damage occurring in at least two separate areas of the CNS at two different points in time (dissemination in space and time). Several tools are used to gather this evidence.

MRI

Magnetic resonance imaging is the most important diagnostic tool for MS. MRI can detect lesions in the brain and spinal cord, show active inflammation with gadolinium contrast enhancement, and track disease activity over time. The location, size, and pattern of lesions help distinguish MS from other conditions. MRI is also used to monitor treatment response, with most neurologists ordering scans annually or more frequently in the early years (Thompson et al., 2018).

Lumbar Puncture

A spinal tap collects cerebrospinal fluid (CSF) for analysis. The presence of oligoclonal bands, which are immunoglobulin proteins that indicate an immune response within the CNS, supports an MS diagnosis. About 85 to 95 percent of people with confirmed MS have oligoclonal bands in their CSF. The procedure is not always required for diagnosis but can be helpful in uncertain cases.

Evoked Potentials

These tests measure the electrical activity in the brain in response to stimulation of specific sensory pathways. Visual evoked potentials (VEP) are most commonly used and can detect slowed nerve conduction even when a person has no visual symptoms, revealing previous subclinical optic nerve damage.

Blood Tests

There is no blood test that can diagnose MS, but blood work is important to rule out conditions that can mimic MS, such as lupus, Sjogren’s syndrome, vitamin B12 deficiency, neuromyelitis optica spectrum disorder (NMOSD), and certain infections.

Disease-Modifying Therapies

DMTs are the backbone of MS treatment. They do not cure the disease, but they reduce the frequency and severity of relapses, slow the accumulation of new lesions, and can significantly delay disability progression. The choice of DMT depends on disease type, severity, patient preferences, and risk tolerance.

Injectable Therapies

Interferons (Avonex, Rebif, Betaseron, Plegridy): Among the earliest DMTs, interferons reduce relapse rates by roughly 30 percent. They modulate the immune response and have a long safety track record. Side effects include flu-like symptoms after injection, injection site reactions, and liver enzyme elevations.

Glatiramer acetate (Copaxone, Glatopa): A synthetic protein that resembles myelin basic protein and appears to redirect the immune response away from myelin. Similar efficacy to interferons with a different side effect profile. Well-established safety in pregnancy compared to most other DMTs (Hauser et al., 2017).

Oral Therapies

Dimethyl fumarate (Tecfidera): Reduces relapses by about 50 percent and has anti-inflammatory and neuroprotective properties. The most common side effects are flushing and gastrointestinal discomfort, which usually improve over time. Requires regular monitoring of lymphocyte counts.

Fingolimod (Gilenya): The first oral DMT approved for MS. It works by trapping lymphocytes in the lymph nodes, preventing them from entering the CNS. Effective in reducing relapses and brain atrophy. Requires first-dose cardiac monitoring and ongoing monitoring for macular edema and infections.

Cladribine (Mavenclad): An immune reconstitution therapy given as short oral courses in year one and year two only. It selectively depletes lymphocytes, and the immune system then rebuilds. Effective for highly active RRMS. An attractive option for people who prefer a treatment-free period between courses.

Infusion Therapies

Ocrelizumab (Ocrevus): An anti-CD20 monoclonal antibody that targets B cells. It is the first and only DMT approved for both RRMS and PPMS. In RRMS, it reduces relapses by about 46 percent compared to interferon. In PPMS, it slowed disability progression. Given as an intravenous infusion every six months (Montalban et al., 2017).

Natalizumab (Tysabri): A highly effective DMT that blocks immune cells from crossing the blood-brain barrier. Reduces relapses by about 68 percent. The main concern is the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with JC virus. Regular JCV antibody testing helps stratify this risk (Bloomgren et al., 2012).

Symptom Management Medications

Alongside DMTs, several medications help manage specific MS symptoms:

• Corticosteroids: High-dose intravenous methylprednisolone (typically three to five days) is the standard treatment for acute relapses. Steroids speed recovery but do not change the ultimate degree of recovery.
• Dalfampridine (Ampyra): A potassium channel blocker that can improve walking speed in some people with MS. About one-third of patients experience a meaningful benefit.
• Baclofen and tizanidine: Commonly prescribed for spasticity. Baclofen can also be delivered intrathecally via a pump for severe, refractory spasticity.
• Fatigue management: Amantadine and modafinil are sometimes used, but non-pharmacological strategies like exercise, energy conservation, and sleep optimization are often more effective long-term.

Integrative and Lifestyle Approaches

A growing body of research supports the role of lifestyle modifications in MS management. These strategies do not replace DMTs but can meaningfully improve quality of life and may even influence disease activity.

Vitamin D

The link between vitamin D and MS is one of the strongest in the integrative medicine space. MS is more common in regions farther from the equator, where sun exposure and vitamin D levels are lower. Low serum vitamin D levels are associated with higher relapse rates and more MRI activity. While no large randomized trial has definitively proven that supplementation changes MS outcomes, many MS neurologists recommend maintaining serum 25-hydroxyvitamin D levels between 40 and 60 ng/mL. The evidence is strong enough that vitamin D supplementation is now considered a reasonable adjunctive strategy (Ascherio et al., 2014).

Exercise

Exercise was once discouraged for people with MS due to concerns about Uhthoff’s phenomenon and fatigue. That thinking has completely reversed. Regular physical activity improves strength, balance, cardiovascular fitness, mood, fatigue, and possibly cognition. A 2019 review of exercise in MS found consistent benefits across multiple symptom domains and called exercise “a disease-modifying treatment” for MS (Motl et al., 2017).

Recommended approaches include a mix of aerobic exercise (walking, cycling, swimming), resistance training, balance work, and flexibility exercises. Aquatic exercise in a cool pool is especially well tolerated. People should start gradually and work with a physical therapist familiar with MS if possible.

Anti-Inflammatory Diet and the Wahls Protocol

While no single diet has been proven to change the course of MS in a large clinical trial, several dietary patterns show promise. The general principle is to emphasize anti-inflammatory foods and reduce processed ones.

The Wahls Protocol, developed by physician Terry Wahls, who herself has MS, is a structured dietary plan that emphasizes nine cups of fruits and vegetables daily (three cups each of leafy greens, sulfur-rich vegetables, and deeply colored produce), along with grass-fed meats, wild-caught fish, and organ meats. A pilot trial showed improvements in fatigue in people with progressive MS (Bisht et al., 2014).

Other dietary approaches that have been studied in MS include the Mediterranean diet, the modified Paleolithic diet, and the Swank diet (a very low saturated fat diet). Most experts agree that a diet rich in vegetables, fruits, whole grains, lean proteins, and omega-3 fatty acids while low in processed foods, sugar, and saturated fat is a reasonable baseline for people with MS.

Meditation and Stress Management

Psychological stress can trigger or worsen MS relapses, and chronic stress takes a toll on quality of life. Mindfulness-based stress reduction (MBSR) has been studied in MS populations and shown to reduce perceived stress, anxiety, depression, and fatigue. A structured MBSR program typically involves eight weeks of guided meditation, body scanning, and gentle yoga (Grossman et al., 2010).

Cooling Strategies

Because heat sensitivity (Uhthoff’s phenomenon) is so common in MS, proactive cooling can make a real difference. Options include cooling vests, cold beverages before and during exercise, pre-cooling in an air-conditioned room before going outside, cold water immersion of the hands and feet, and scheduling outdoor activities for cooler times of the day. The Multiple Sclerosis Association of America offers a free cooling equipment program for people with MS who demonstrate heat sensitivity.

Cannabis for Spasticity

Cannabis-based treatments have received significant research attention for MS-related spasticity. Nabiximols (Sativex), an oromucosal spray containing THC and CBD in a 1:1 ratio, is approved in many countries specifically for MS spasticity that has not responded to other treatments. Clinical trials have shown it provides meaningful relief for about 40 to 50 percent of patients. However, it is not yet approved in the United States (Novotna et al., 2011).

In jurisdictions where medical cannabis is available, some people with MS use it for spasticity, pain, and sleep. It is important to discuss this with your neurologist, as cannabis can interact with other medications and may have cognitive effects that overlap with MS-related cognitive changes.

MS and Pregnancy

MS predominantly affects women of childbearing age, making pregnancy planning a frequent topic. The good news is that MS itself does not reduce fertility, and pregnancy is generally safe for both mother and baby.

Relapse rates actually decrease during pregnancy, especially in the third trimester, likely due to the naturally immunosuppressive state of pregnancy. However, there is an increased risk of relapse in the first three to six months postpartum.

The biggest challenge is medication management. Most DMTs must be stopped before conception, and the washout period varies by drug. Some, like glatiramer acetate, are considered relatively safe during pregnancy, while others, like fingolimod, require careful planning. Breastfeeding may offer some protection against postpartum relapses. Every pregnancy in the context of MS should be planned in close collaboration with both a neurologist and an obstetrician (Dobson et al., 2019).

Managing Fatigue

Because fatigue is the most common and often most debilitating symptom, it deserves dedicated attention. Effective fatigue management usually involves multiple strategies used together.

• Energy conservation: Pacing activities throughout the day, prioritizing important tasks for peak energy times, and taking strategic rest breaks.
• Sleep optimization: Addressing sleep disruptions, which may include nocturia, spasticity, pain, restless legs, or sleep apnea. Good sleep hygiene practices are fundamental.
• Exercise: Counterintuitive as it may seem, regular moderate exercise is one of the best treatments for MS fatigue. Cardiovascular exercise has the strongest evidence.
• Temperature management: Avoiding overheating, since heat-induced fatigue is common.
• Treating contributing factors: Depression, anemia, thyroid dysfunction, medication side effects, and deconditioning can all worsen fatigue and may be treatable.
• Cognitive behavioral therapy: CBT has been shown to reduce MS fatigue in randomized controlled trials and may be more effective than medications.

Prognosis With Modern Treatment

The prognosis for MS has improved substantially over the past two decades. With early diagnosis and effective DMT, many people with RRMS maintain their neurological function for years or even decades. Key factors that are associated with a more favorable prognosis include younger age at onset, female sex, relapsing-remitting course, low lesion burden on initial MRI, and early treatment with a highly effective DMT.

The concept of NEDA (No Evidence of Disease Activity) has become an important treatment goal. NEDA means no relapses, no disability progression, and no new or enlarging MRI lesions. While NEDA is not always achievable, it provides a clear benchmark for evaluating whether a given treatment is working well enough (Giovannoni et al., 2017).

Life expectancy for people with MS is now only modestly reduced compared to the general population, and the gap continues to narrow as treatments improve. The MS of today is a very different disease from the MS of the 1990s.

Finding an MS Specialist

Not all neurologists have extensive experience with MS. Because treatment decisions in MS are becoming increasingly sophisticated, seeing a neurologist who specializes in MS, or even a neuroimmunologist, can make a significant difference in outcomes.

MS specialists are often found at academic medical centers and MS centers of excellence. The National MS Society maintains a searchable database of healthcare providers. When evaluating a potential neurologist, consider:

• How many MS patients does the practice see?
• Is the physician familiar with all currently available DMTs, including newer options?
• Does the practice offer access to support services like physical therapy, occupational therapy, mental health support, and social work?
• How are relapses handled? Is there after-hours access?
• Does the neurologist follow a treat-to-target approach (aiming for NEDA)?

A good MS care team should include not just a neurologist but also a primary care physician, physical therapist, occupational therapist, mental health provider, and urologist if bladder symptoms are present. Many MS centers offer coordinated multidisciplinary care.

Living Well With MS

MS is a chronic condition that requires ongoing management, but it does not have to prevent a meaningful, active life. People with MS run businesses, raise families, travel, and pursue careers. The keys to long-term well-being include:

• Staying on an effective DMT and adjusting if disease activity breaks through.
• Keeping physically active within your abilities.
• Building a strong relationship with a knowledgeable healthcare team.
• Prioritizing mental health and seeking support for depression and anxiety, which are common in MS.
• Connecting with the MS community through organizations like the National MS Society or MS-specific online groups.
• Staying informed about new research and treatment options.
• Advocating for yourself in the healthcare system.

MS research is moving fast. New DMTs, remyelination therapies, and biomarkers for disease activity are all under active investigation. There is genuine reason for optimism about the future of MS care.

Related Reading

• Autoimmune Disease: What You Need to Know
• Vitamin D: What You Need to Know for Optimal Health
• The Anti-Inflammatory Diet: A Practical Guide
• Chronic Fatigue: Causes, Diagnosis, and Solutions
• Meditation for Health: Evidence-Based Benefits and How to Start

Frequently Asked Questions

Do disease-modifying therapies cure MS?

No. The guide is clear that DMTs do not cure the disease. They work by reducing the frequency and severity of relapses. Reported effects vary by drug: interferons reduce relapse rates by roughly 30 percent, dimethyl fumarate by about 50 percent, and natalizumab by about 68 percent, while ocrelizumab reduces relapses by about 46 percent compared to interferon in RRMS.

What are the main side effects and safety risks of MS drugs?

Risks differ by drug. Interferons can cause flu-like symptoms, injection site reactions, and liver enzyme elevations. Dimethyl fumarate commonly causes flushing and gastrointestinal discomfort and requires monitoring of lymphocyte counts, while fingolimod needs first-dose cardiac monitoring and ongoing checks for macular edema and infections. Natalizumab’s main concern is progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection linked to the JC virus.

Does vitamin D help with MS?

Low serum vitamin D levels are associated with higher relapse rates and more MRI activity, and many MS neurologists recommend maintaining levels in the 40 to 60 ng/mL range. That said, the guide notes no large randomized trial has definitively proven that supplementation changes MS outcomes, so it is a supportive measure rather than a proven treatment.

Can diet and lifestyle changes affect MS?

The guide describes exercise as improving strength, balance, cardiovascular fitness, mood, fatigue, and possibly cognition, and cites a 2019 review calling it a disease-modifying treatment. A pilot trial of the Wahls Protocol showed improvements in fatigue in people with progressive MS, and mindfulness-based stress reduction has been shown to reduce perceived stress, anxiety, depression, and fatigue. Still, no single diet has been proven to change the course of MS in a large clinical trial.

Is cannabis effective for MS symptoms, and is it approved in the US?

Nabiximols (Sativex) is used for MS spasticity, and clinical trials show it provides meaningful relief for about 40 to 50 percent of patients. It is approved in many countries specifically for MS spasticity but is not yet approved in the United States. Cannabis can interact with other medications and may have cognitive effects that overlap with MS-related cognitive changes, so it should be discussed with a neurologist.

Who gets MS and what are the different types?

MS affects about 2.8 million people worldwide, with diagnosis most common between ages 20 and 40. Relapsing-remitting MS accounts for about 85 percent of initial diagnoses and is two to three times more common in women, while primary progressive MS makes up about 10 to 15 percent of cases and affects men and women roughly equally. The transition to secondary progressive MS typically happens 10 to 20 years after initial diagnosis.

References

1. Thompson, A. J., Baranzini, S. E., Geurts, J., Hemmer, B., & Ciccarelli, O. (2018). Multiple sclerosis. The Lancet, 391(10130), 1622-1636. doi:10.1016/S0140-6736(18)30481-1
2. Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018). Multiple sclerosis. New England Journal of Medicine, 378(2), 169-180. doi:10.1056/NEJMra1401483
3. Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012). Clinically isolated syndromes. The Lancet Neurology, 11(2), 157-169. doi:10.1016/S1474-4422(12)70098-5
4. Montalban, X., Hauser, S. L., Kappos, L., et al. (2017). Ocrelizumab versus placebo in primary progressive multiple sclerosis. New England Journal of Medicine, 376(3), 209-220. doi:10.1056/NEJMoa1606468
5. Penner, I. K., & Paul, F. (2017). Fatigue as a symptom or comorbidity of neurological diseases. Nature Reviews Neurology, 13(11), 662-675. doi:10.1177/1352458517709385
6. Chiaravalloti, N. D., & DeLuca, J. (2008). Cognitive impairment in multiple sclerosis. The Lancet Neurology, 7(12), 1139-1151. doi:10.1038/nrneurol.2011.196
7. Thompson, A. J., Banwell, B. L., Barkhof, F., et al. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology, 17(2), 162-173. doi:10.1016/S1474-4422(17)30470-2
8. Hauser, S. L., Bar-Or, A., Comi, G., et al. (2017). Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. New England Journal of Medicine, 376(3), 221-234. doi:10.1056/NEJMoa1614583
9. Bloomgren, G., Richman, S., Hotermans, C., et al. (2012). Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New England Journal of Medicine, 366(20), 1870-1880. doi:10.1056/NEJMoa1104318
10. Ascherio, A., Munger, K. L., White, R., et al. (2014). Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurology, 71(3), 306-314. doi:10.1001/jamaneurol.2015.36
11. Motl, R. W., Sandroff, B. M., Kwakkel, G., et al. (2017). Exercise in patients with multiple sclerosis. The Lancet Neurology, 16(10), 848-856. doi:10.1177/1352458519845862
12. Bisht, B., Darling, W. G., Grossmann, R. E., et al. (2014). A multimodal intervention for patients with secondary progressive multiple sclerosis: feasibility and effect on fatigue. Journal of Alternative and Complementary Medicine, 20(5), 347-355. doi:10.1016/j.jns.2014.05.056
13. Grossman, P., Kappos, L., Gensicke, H., et al. (2010). MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology, 75(13), 1141-1149. doi:10.1212/WNL.0b013e3181df0b1c
14. Novotna, A., Mares, J., Ratcliffe, S., et al. (2011). A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology, 18(9), 1122-1131. doi:10.1111/ene.12197
15. Dobson, R., Dassan, P., Roberts, M., Giovannoni, G., Nelson-Piercy, C., & Brex, P. A. (2019). UK consensus on pregnancy in multiple sclerosis: Association of British Neurologists guidelines. Practical Neurology, 19(2), 106-114. doi:10.1016/S1474-4422(18)30066-9
16. Giovannoni, G., Turner, B., Gnanapavan, S., et al. (2017). Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Multiple Sclerosis and Related Disorders, 4(4), 329-333. doi:10.1002/ana.24932